Michael Egholm - 21 Mar 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role: President & CEO, Director
Signature: /s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact
Issuer symbol: LAB
Transactions as of: 21 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 24 Mar 2025, 18:31:57 UTC
Previous filing: 24 Feb 2025
Next filing: 08 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LAB	Common Stock	Award	$0	+1,188,333	+82%	$0.000000	2,636,006	21 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LAB	Stock Option (Right to buy)	Award	$0	+1,782,500		$0.000000	1,782,500	21 Mar 2025	Common Stock	1,782,500	$1.21	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2025 and the remaining RSUs vesting in equally quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
F2	The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2025, with the remaining shares vesting in equally quarterly installments, thereafter, subject to the Reporting Person's continued service through the applicable vesting date.